Pancreatic/Thyroid/Other Endocrine Cancers
Unlike most lesion medical image datasets currently available, which can detect only 1 type of lesion, DeepLesion has much diversity and contains critical radiology findings from across the body, including lung nodules, liver tumors, and enlarged lymph nodes.
Infugem utilizes a novel technology that enables cytotoxic oncology products to be premixed in a sterile setting and to be supplied to prescribers in RTA infusion bags.
In the first 2 years after cancer diagnosis, the excess risk for diabetes was highest, and it remained elevated throughout follow-up.
Thierry Conroy, MD, from the Institut de Cancérologie de Lorraine in Vandœuvre-lès-Nancy, France, and colleagues randomized patients with histologically proven pancreatic ductal adenocarcinomas, 21 to 84 days after resection, to six cycles of gemcitabine (arm A; 246 patients) or 12 cycles of mFOLFIRINOX (arm B; 247 patients).
Study data showed 57% of evaluable patients (N=23) had a partial response and 4% achieved a complete response. Among the 14 responders, 64% did not have significant tumor growths for ≥6 months.
The hazard ratio for pancreatic cancer was 1.48 for long-term users of CCBs (more than 3 years) versus never users; the correlation was slightly attenuated, but remained significant, in the competing risk model.
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor.
"We believe we've developed the first prognostic model that, once confirmed in larger studies, could provide a critical decision-making tool for clinicians," said lead author Gregory Russell Pond, PhD.
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
Lutathera is a radiolabeled somatostatin analog indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.
Azedra, a high-specific-activity radiotherapeutic product, is a substrate for the norepinephrine reuptake transporter that is highly expressed on the cell surface of neuroendocrine tumors.
The researchers found that ulixertinib exposure was dose-proportional to the RP2D and almost completely inhibited ERK activity in whole blood.
There was a 6.2-fold difference in thyroidectomy rates across U.S. regions (range, 22 to 139 per 100,000 Medicare beneficiaries).
Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.
The researchers found that the men with early-stage prostate cancer who did not already have cardiovascular disease, but who received ADT had an 81% higher risk for heart failure.
The researchers reported the resensitization of chemoresistant PDAC cells by curcumin through inhibition of the PRC2-PVT1-c-Myc axis.
Clinical trials of pamrevlumab are currently ongoing for conditions such as idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.
That FDA has approved Xermelo (telotristat ethyl) tablets as the first oral treatment for carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.
Regular aspirin use is associated with reduced risk of pancreatic cancer in a Chinese cohort, according to a study published online in Cancer Epidemiology, Biomarkers & Prevention.
For patients with papillary thyroid cancer (PTC), patient age is associated with death in a linear fashion, with no apparent age cut point demarcating survival difference, according to a study published online in the Journal of Clinical Oncology.
For pancreatic ductal adenocarcinoma (PDAC) patients with diabetes, metformin treatment was associated with an increase in survival. Those were the findings of a new study published in the American Journal of Gastroenterology.